| BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk |
NCT01697618: Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
|
|
| Completed | 2 | 13 | Europe | biphasic insulin aspart 30, biphasic human insulin 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 11/98 | 11/98 | | |
NCT01526980: Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes |
|
|
| Completed | 2 | 31 | Europe | biphasic insulin aspart 30, biphasic insulin aspart 70, biphasic human insulin 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 11/02 | 11/02 | | |
NCT00613951 / 2007-002462-35: Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes |
|
|
| Completed | 2 | 182 | Europe | insulin degludec/insulin aspart, biphasic insulin aspart, metformin | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 08/08 | 08/08 | | |
NCT00842361: Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 66 | Japan | insulin degludec/insulin aspart, biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 06/09 | 06/09 | | |
